NCT04569032 2026-02-18
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
Phase 2 Completed
Seagen Inc.
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Aileron Therapeutics, Inc.
Daiichi Sankyo
Affimed GmbH
Dizal Pharmaceuticals